Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabell Ge

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Therapeutische Umschau. Revue Therapeutique|November 18, 2025
[Common features and core disciplines of integrative oncology]Natalie Kalbermatten, Chantal Berna, Natacha Bordry, et al.
Transfusion|February 11, 2017
Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphomaIsabell Ge, Rima M Saliba, Farzaneh Maadani, et al.
Cancer|July 13, 2016
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantationSameh Gaballa, Isabell Ge, Riad El Fakih, et al.
JCO Precision Oncology|September 11, 2020
Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center ExperienceRouven Hoefflin, Anna-Lena Geißler, Ralph Fritsch, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Therapeutische Umschau. Revue Therapeutique|November 18, 2025
[Common features and core disciplines of integrative oncology]Natalie Kalbermatten, Chantal Berna, Natacha Bordry, et al.
Transfusion|February 11, 2017
Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphomaIsabell Ge, Rima M Saliba, Farzaneh Maadani, et al.
Cancer|July 13, 2016
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantationSameh Gaballa, Isabell Ge, Riad El Fakih, et al.
JCO Precision Oncology|September 11, 2020
Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center ExperienceRouven Hoefflin, Anna-Lena Geißler, Ralph Fritsch, et al.
Pageof 2